The dysregulation of the mesenchymal-epithelial transition factor (c-MET) signaling pathway is linked to the development and drug resistance of non-small cell lung cancer (NSCLC), highlighting the need for small-molecule inhibitors targeting c-MET. In this study, we identified six potential c-MET inhibitors from a compound library using structure-based and AI-based virtual screening. Four compounds demonstrated c-MET inhibitory activity, with compound 2 exhibiting potent inhibition at an IC₅₀ of 40.1 nM. Further studies showed that compound 2 effectively inhibited NSCLC cell proliferation, comparable to that of positive controls. ADMET predictions indicate favorable drug-like properties, suggesting its potential as a novel c-MET inhibitor. Molecular dynamics simulations revealed that compound 2 stabilizes its conformation through interactions with Ala1221, Pro1158, and Lys1110, providing valuable insights for further drug development.

2025-11-01·CANCER LETTERS

Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress

Article

作者: Saad, Eddy ; Machaalani, Marc ; Pal, Soumitro ; Buerger, Florian ; Sabarwal, Akash ; Eid, Marc ; Lee, Dongwon ; Sasamoto, Yuzuru ; Choueiri, Toni K ; Rawat, Laxminarayan ; Tabasum, Saba ; Mary Lee, Gwo-Shu ; Freedman, Matthew L ; Semaan, Karl ; Yang, Yifan ; Wedel, Johannes ; Hodi, F Stephen ; Balan, Murugabaskar ; Ascione, Josie

The mechanisms underlying therapeutic resistance to c-Met/receptor tyrosine kinase (RTK) inhibitors in renal cancer remain unexplored. In renal cell carcinoma (RCC) cells, both AXL and c-Met are highly upregulated. Notably, we found that prolonged treatment with the c-Met/RTK inhibitor, cabozantinib (Cabo), a standard treatment for advanced-stage RCC, markedly increased total c-Met levels and promoted renal cancer cell proliferation. This effect was confirmed not only in vitro but also in murine models and renal tumor tissues from Cabo-treated patients. At lower concentrations (1 nM and 10 nM), Cabo treatment failed to inhibit HGF (c-Met ligand)-induced c-Met phosphorylation. Instead, it further enhanced receptor phosphorylation and downstream signaling events for tumor growth. Additionally, Cabo treatment induced AXL-c-Met association and disrupted the physiological degradation of c-Met. However, inhibition or knockout of AXL could significantly overcome therapeutic resistance to c-Met inhibitor(s). It triggered apoptotic cell death through increased oxidative stress and inhibition of the redox-sensitive transcription factor, Nrf2 and its effector molecule, heme oxygenase-1 (HO-1). We also generated Cabo-resistant RCC cells and observed a marked upregulation of both c-Met and AXL in these cells. Epigenomic profiling revealed significant differences between Cabo-resistant and Cabo-sensitive RCC cells. Importantly, inhibition of AXL either using a potent inhibitor, TP-0903, or through genetic silencing resensitized the resistant cells to Cabo-induced cell death. Together, our findings highlight AXL as a key driver of therapeutic resistance to c-Met inhibitors. A combination therapy targeting both c-Met and AXL in renal cancer could be a promising strategy to overcome the acquired resistance to c-Met inhibitors through increased oxidative stress.

2025-09-01·MedComm

Identification of c‐Met on Tumor Cells as a Novel Receptor for B7‐H3 Entails Implications for Cancer Cell Stemness and Targeted Therapy

Article

作者: Fu, Fengqing ; Huang, Lili ; Hu, Yizhou ; Irene, Ylivinkka ; Cao, Lei ; Feng, Yangyang ; Xu, Yunyun ; Wang, Jian ; Liu, Wanli ; Lu, Binfeng ; Markku, Varjosalo ; Li, Huini ; Zhan, Shenghua ; Zhang, Xueguang ; Huang, Xue ; Zhang, Guangbo ; Jorma, Keski‐Oja

ABSTRACT:

The immune checkpoint molecule B7‐H3 is upregulated in many solid tumors, and B7‐H3‐targeted immunotherapies are in clinical trials. Recently, a growing body of research has highlighted the presence of tumor cell intrinsic while immune cell‐independent functions of B7‐H3 in tumorigenesis and cancer cell stemness. However, its receptors and mechanisms of action on cancer cells remain poorly understood. Here, we report that c‐Met, a canonical oncogenic receptor tyrosine kinase on cancer cells, is identified as a novel binding protein for B7‐H3. The binding between c‐Met and B7‐H3 directly activates the c‐Met/STAT3 signaling cascade, promoting cancer cell stemness in both colorectal cancer and glioblastoma‐derived tumor cells. More importantly, we evaluated the translational implications of this discovery by screening a high‐affinity antibody designed to selectively disrupt the interaction between B7‐H3 and c‐Met, demonstrating strong anti‐tumor activities, surpassing that of the B7‐H3‐specific antibody lacking the blocking capability. Combination therapy of this newly developed interaction blocking antibody with c‐Met inhibitor results in significantly improved therapeutic effects in inhibiting tumor growth. These findings shed light on previously undisclosed interaction of B7‐H3 to c‐Met on cancer cells, thereby indicating a new mechanism of cancer cell stemness and intervention pathway of molecular targeted therapy.

项与 c-Met inhibitor(Jiangsu Aosaikang) 相关的新闻（医药）

2025-12-23

·BioSpace

Apollomics Reports First Half 2025 Financial Results

FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2025 ended June 30, 2025. First Half 2025 Financial Results Ended June 20, 2025 Cash, cash equivalents, bank deposits and money market funds as of June 30, 2025, were $2.1 million, compared to $9.8 million as of December 31, 2024. Based on current projections, the Company believes its cash position is sufficient to fund planned operations into the third quarter of 2026. Research and development (R&D) expenses were $4.6 million, including share-based compensation of $0.8 million, for the first half of 2025, compared to $16.9 million, including share-based compensation of $3.7 million, for the first half of 2024. General and administrative (G&A) expenses were $14.5 million, including share-based compensation of $2.5 million, for the first half of 2025, compared to $10.2 million, including share-based compensation of $4.5 million, for the first half of 2024. Net loss for the first half of 2025 was $(12.5) million, or $(11.37) per basic and diluted share, compared to a net loss of $(35.2) million, or $(37.53) per basic and diluted share, for the first half of 2024. About Apollomics Inc. Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit . Cautionary Statement Regarding Forward-Looking Statements This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2025, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents or to be by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. Investor Contacts Peter Lin, Chief Financial Officer Apollomics, Inc. 1-650-209-4055 peter.lin@apollomicsinc.com Peter Vozzo ICR Healthcare 1-443-213-0505 Peter.Vozzo@icrhealthcare.com APOLLOMICS INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (All amounts in thousands of $) As of June 30, 2025 (Unaudited) As of December 31, 2024 Non-current assets Plant and equipment, net $ 10 $ 92 Right-of-use assets 670 927 Intangible assets, net 228 1,737 Rental deposits 82 75 Total non-current assets 990 2,831 Current assets Deposits, prepayments and deferred expenses 835 501 Accounts receivable 7,200 — Cash and cash equivalents 2,094 9,766 Total current assets 10,129 10,267 Total assets 11,119 13,098 Current liabilities Other payables and accruals 10,269 7,166 Lease liabilities, current portion 203 233 Total current liabilities 10,472 7,399 Net current (liabilities) assets (343 ) 2,868 Total assets less current liabilities 647 5,699 Non-current liabilities Lease liabilities, non-current portion 541 733 Warrant liabilities at fair value through profit and loss (“FVTPL”) 486 102 Other non-current liabilities 4,018 — Total non-current liabilities 5,045 835 Net (liabilities) assets (4,398 ) 4,864 Equity Share capital 11 11 Share premium 666,528 666,528 Reserves 42,422 39,148 Accumulated deficits (713,359 ) (700,823 ) Total (deficit) equity $ (4,398 ) $ 4,864 APOLLOMICS INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (UNAUDITED) (All amounts in thousands of $, except for per share data) Six Months Ended June 30, 2025 2024 Revenue $ 8,500 $ — Other income 83 1,737 Foreign exchange losses (77 ) (2 ) Fair value change of financial assets at FVTPL — 198 Fair value change of financial liabilities at FVTPL (384 ) 164 Research and development expenses (4,620 ) (16,926 ) Administrative expenses (14,488 ) (10,153 ) Impairment of intangible assets (1,500 ) (10,000 ) Finance costs (35 ) (134 ) Other expense (14 ) (90 ) Loss before taxation (12,535 ) (35,206 ) Income tax expenses (1 ) 0 Loss and total comprehensive loss for the period, net of taxation, attributable to owners of the Company $ (12,536 ) $ (35,206 ) Loss per share Basic loss per common share $ (11.37 ) $ (37.53 ) Diluted loss per common share $ (11.37 ) $ (37.53 ) Weighted average number of common shares outstanding – Basic and Diluted 1,103 938

财报临床2期临床1期

2025-11-18

·GlobeNewswire-Health Care

Apollomics Announces Changes to its Board of Directors and Composition of Committees

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees. On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh’s resignation was not related to any disagreement with the Company. Pursuant to a meeting of the Board on November 16, 2025, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy resulting from Mr. Hsueh’s resignation. Dr. Ya-Chi (Claudia) Huang will also replace Mr. Po-Jen Hsueh as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee. Following these changes and the previously announced appointments of directors, the Company’s Board is comprised of the following seven members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Moses Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang are independent directors. Biographical Information of the New Director Dr. Ya-Chi (Claudia) Huang brings to the Board extensive experience in biotechnology investment, corporate governance, and research and development across Taiwan's biopharmaceutical industry. Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has successfully completed investments in multiple companies and manages their post-investment operations. She also serves as a director of AngenMed Therapeutics. Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond's portfolio companies. She participated in Diamond Biofund's IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, and contributed to a significant increase in Fubon Securities' investment banking profits. Dr. Huang's scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award. Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University. About Apollomics Inc.Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit www.apollomicsinc.com. Cautionary Statement Regarding Forward-Looking StatementsThis press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. Investor Contacts: Apollomics: Peter Lin, Chief Financial Officer Apollomics, Inc. Phone: 1-650-209-4055 Email: peter.lin@apollomicsinc.com

临床2期高管变更IPO

2025-10-13

·PRNewswire

EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

DOVER, Del., Oct. 13, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors targeting escape mutations in hematologic malignancies and solid tumors, today announced the presentation of data for its brain- and lung-permeable pan-EGFR inhibitor, ZE77-0273 is a reversible small-molecule drug candidate that demonstrates broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC), a high selectivity index versus wild-type EGFR, and a wide therapeutic window characterized by excellent safety and tolerability. About Eilean Therapeutics Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and solid tumors. Utilizing its proprietary hybrid AI/ML drug design platform, the company leverages proprietary partner data, advanced chem/bio tools, and deep domain expertise to identify highly valuable molecular targets, accelerate drug discovery, and optimize the development of highly differentiated therapies. Eilean's oncology programs for therapy-resistant lung cancer include best-in-class reversible pan-EGFR inhibitor, c-Met inhibitor, and pan-KRAS molecular glue. For more information, visit Media Contact: Amy Burd, PhD, CSO Eilean Therapeutics, Inc. Email: [email protected] SOURCE Eilean Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

AACR会议

100 项与 c-Met inhibitor(Jiangsu Aosaikang) 相关的药物交易

登录后查看更多信息